XJZY(002332)2024-10-25 08:41Financial Performance - The company's revenue for Q3 2024 was ¥1,099,159,748.99, a decrease of 1.80% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥190,458,380.68, an increase of 12.17% year-over-year[2] - The net profit after deducting non-recurring gains and losses was ¥189,686,609.85, reflecting a 14.68% increase compared to the previous year[2] - Basic earnings per share for Q3 2024 was ¥0.1925, up 12.20% from the same period last year[2] - Total operating revenue for the third quarter was CNY 3,237,007,358.82, slightly down from CNY 3,237,459,693.20 in the previous year, representing a decrease of 0.01%[12] - The net profit for the third quarter of 2024 was CNY 542,697,542.20, an increase of 14.9% compared to CNY 471,952,130.64 in the same period last year[13] - The total profit for the quarter was CNY 627,710,393.41, an increase of 15.6% from CNY 543,288,658.99 in the same period last year[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,907,740,160.80, a decrease of 1.22% from the end of the previous year[2] - The company's equity attributable to shareholders increased by 3.94% to ¥6,014,143,118.38 compared to the end of the previous year[2] - The company's total assets amounted to CNY 6,907,740,160.80, compared to CNY 6,992,835,052.50 in the previous period, indicating a decrease of approximately 1.22%[11] - Total liabilities decreased to CNY 839,155,775.33 from CNY 1,162,789,279.07, a significant reduction of about 27.8%[11] Cash Flow - Cash flow from operating activities decreased by 55.55% to ¥217,426,077.84, mainly due to reduced cash received from sales[5] - The net cash flow from operating activities decreased to CNY 217,426,077.84, compared to CNY 489,132,192.50 in the same period last year, reflecting a decline of 55.6%[15] - The company experienced a net cash outflow from investing activities of CNY 141,975,100.62, compared to a net outflow of CNY 110,738,559.67 in the same period last year[16] - The net cash outflow from financing activities was CNY 415,007,804.20, compared to CNY 396,759,794.01 in the previous year, indicating an increase in cash outflow[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,944[6] - The largest shareholder, Xianju County Industrial Investment Development Group Co., Ltd., holds 21.55% of the shares, totaling 213,221,808 shares[7] Research and Development - Research and development expenses increased by 32.46% to ¥45,272,700, primarily due to increased R&D investment[5] - Research and development expenses increased to CNY 184,732,549.63, up from CNY 139,459,816.96, reflecting a growth of about 32.4%[12] Inventory and Receivables - Accounts receivable increased from 551,695,395.67 RMB to 674,710,064.93 RMB, representing a growth of about 22.3%[9] - Inventory decreased from 922,877,229.59 RMB to 894,870,127.93 RMB, a reduction of approximately 3%[9] Future Outlook - Future outlook includes plans for market expansion and potential new product launches, aiming to enhance competitive positioning in the pharmaceutical sector[12] - The company is focusing on strategic acquisitions to bolster its market presence and diversify its product offerings[12] Other Information - The company has ongoing construction projects with a value of 717,993,266.13 RMB, up from 522,168,092.07 RMB, indicating an increase of approximately 37.5%[9] - The company has not reported any new product launches or technological developments in this quarter[8] - There are no significant mergers or acquisitions reported during this period[8] - The company reported a decrease in other comprehensive income, with a net amount of CNY -5,397,470.36 compared to CNY 25,335,128.82 in the previous year[13] - The company reported a total comprehensive income of CNY 537,300,071.84 for the quarter, compared to CNY 497,287,259.46 in the previous year, representing an increase of 8.1%[13]